Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placental-derived autologous mesenchymal stem cells for bronchopulmonary dysplasia in premature infants
ChiCTR2000036324Phase 2Not yet recruiting
- Sponsor
- PLA Army Specialty Medical Center
- Start
- Aug 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of placental-derived autologous mesenchymal stem cells in bronchopulmonary dysplasia (BPD) (2 arms), sponsored by PLA Army Specialty Medical Center. Primary endpoints: Serious adverse event and Moderate to severe bronchopulmonary dysplasia. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
placental-derived autologous mesenchymal stem cells
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on ChiCTR2000036324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036324.